Teva wins EU approval for biosimilar Neupogen

European authorities have approved Teva Pharmaceutical Industries' biosimilar version of Neupogen, Amgen's best-selling treatment for neutropenia, the Israeli generic drugmaker said on Tuesday.

The details can be read here.